Latest Breaking News On - Oakrum pharma - Page 1 : vimarsana.com

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

Expect Q1 2024 product launch Nitisinone market estimated to be more than $50 million annually Eton will offer Eton Cares support program to all patients DEER PARK, Ill., Oct. 04,.

United statesLisam wilsonSean brynjelsenEton pharmaceuticalsSite communications incOakrum pharmaEton pharmaceuticals incExchange commissionDrug administrationCompany nasdaqEton caresNitisinone capsulesCarglumic acidBetaine anhydrousOrphan drug designationPrivate securities litigation reform act

Eton Pharmaceuticals (ETON) Acquires FDA-Approved Ultra-Rare Disease Product Nitisinone

Eton Pharmaceuticals (ETON) Acquires FDA-Approved Ultra-Rare Disease Product Nitisinone
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSean brynjelsenDrug administrationEton pharmaceuticals incEton pharmaceuticalsOakrum pharmaEton pharmaceuticals nasdaqNitisinone capsulesCarglumic acidEton cares

Toxoplasmosis Treatment Market Size Worth USD 1 09 Billion, Globally, by 2031 at 4 8% CAGR: AMR

Toxoplasmosis is an infection caused by common parasite, which is found in cat feces and in contaminated food. This parasite is known as Toxoplasma gondii. The symptoms of toxoplasmosis disease include body aches and pain, headache, fatigue, fever, and swollen lymph nodes. In addition, people with weakened immune sy.

Saudi arabiaUnited statesSouth africaUnited kingdomTamil naduDavid correaOakrum pharmaKaiser permanenteOrganics ltdManus aktteva biopharmaDr reddy laboratories ltdVyera pharmaceuticalsTop companiesDrug storesRoute of administrationMarket research

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and R

Second Quarter 2022 Results: Net revenues of $73.9 million, net loss available to common shareholders of $(15.3) million and diluted GAAP loss per share of $(0.94) – Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin) net sales of $10.2 million Ad.

United statesNikhil lalwaniLisam wilsonMeredithw cookOakrum pharmaExchange commissionOakrum pharmaceuticalsDrug administrationSite communications incPharmaceuticals incBusiness developmentSecond quarterRare diseaseRepository corticotrophin injectionPer shareGeneral counsel

ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin Gel

08.08.2022 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and six months ended June 30, 2022. “Second quarter net revenues of $73.9 million represent a new quarterly record .

United statesOakrum pharmaExchange commissionDrug administrationPharmaceuticals incBusiness developmentLaunch updateUnited healthcareGrowth engine updateCortrophin gelNet revenuePurified cortrophin gelNorth americanPrivate securities litigation reformAnnual reportMonths ended june